Artiva Biotherapeutics, Inc. — Income Charts
1 years of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$251K
R&D
$50M
D&A
$2M
Operating Income
$-67M
EBITDA
$-65M
Other Income/Expense
$133M
Pretax Income
$65M
Tax Provision
$0
Net Income
$-65M
Operating Margin
-26805.6%
Net Margin
-26045.0%
Effective Tax Rate
0.0%
Deferred Tax Assets
$5M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$63M
Tax Credit Carryforwards
$8M
NOL Carryforwards
$30M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.4%
Operating Lease Cost
$4M
Revenue YoY Variation
-99.3%
Income YoY Variation
-119.4%